Press release
Parkinson's Disease Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in Parkinson's Disease Research. Learn more about our innovative pipeline today! @ Parkinson's Disease Pipeline Outlook [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Parkinson's Disease Pipeline Report
* June 2024:- Cerevance Beta Inc .- This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.
* June 2024:- S.Biomedics Co., Ltd.- A Single Center, Open, Single Dosing, Dose-escalation, Phase 1/2a Study to Evaluate the Safety and Exploratory Efficacy of Embryonic Stem Cell-derived A9 Dopamine Progenitor Cell (A9-DPC) Therapy in Patients With Parkinson's Disease
* DelveInsight's Parkinson's Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson's Disease treatment.
* The leading Parkinson's Disease Companies such as Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Prevail Therapeutics, Luye Pharma Group Ltd, FAScinate Therapeutics Inc., Neurocrine Biosciences, Sangamo Therapeutics, AstraZeneca, Hoffmann-La Roche, Brain Neurotherapy Bio, Inc, Annovis Bio Inc, Anavex Life Sciences Corp, Alexza Pharmaceuticals, Inc., Pharma Two B Ltd., MeiraGTx, LLC, BioVie Inc., Takeda Pharmaceuticals, and others.
* Promising Parkinson's Disease Therapies such as Apomorphine Infusion, CVN424 150 mg, MT101-5, BIA 28-6156 10 mg, RO7046015, ND0612 , and others.
Stay informed about the cutting-edge advancements in Parkinson's Disease Treatments. Download for updates and be a part of the revolution in Neurology care @ Parkinson's Disease Clinical Trials Assessment [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Parkinson's Disease Emerging Drugs Profile
* Tavapadon: Cerevel Therapeutics
Tavapadon is an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes. The drug is designed to improve motor symptoms by selectively targeting and binding to dopamine D1/D5 receptor subtypes and to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor over excitation and desensitization caused by full agonists, which can lead to dyskinesia's and exacerbation of "off" time. Currently it is in Phase III stage of clinical trial evaluation to treat Parkinson's disease.
* IkT-148009: Inhibikase Therapeutics
IkT-148009 is a potent, selective small-molecule, oral medication targeting the underlying biological mechanism with the goal of halting disease progression and reversing functional loss. The drug is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms. IkT-148009 is currently being evaluated in the Phase II studies for the treatment of Parkinson's disease.
* NLY01: Neuraly
NLY01 is a first-in-Class GLP-1R agonist for Neurodegenerative Disease. It is a pegylated exendin-4 analogue of glucagon like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood-brain barrier (BBB) and its receptor (GLP-1R) is highly expressed on glial cells. Currently the drug is being evaluated in Phase II for the treatment of Parkinson's disease.
* PT320: Peptron
PT320 (Exenatide) is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) belonging to the group of incretin mimetics. It is a synthetic version of exendin-4, a hormone found in the saliva of the Gila monster, and it is a 39-amino-acid peptide, inducing insulin secretion. Exenatide binds to the intact human GLP-1 receptor in a similar way to the human GLP-1. Currently the drug is being evaluated in Phase II for the treatment of Parkinson's disease.
* BIIB094: Biogen
BIIB094, also known as ION859 is an investigational antisense medicine designed to inhibit the production of the leucine-rich repeat kinase 2 (LRRK2) protein as a potential therapy. It binds the mRNA for leucine-rich repeat kinase 2 and mediates its degradation. This results in lower LRRK2 protein levels. Currently the drug is being evaluated in Phase II for the treatment of Parkinson's disease.
Learn more about Parkinson's Disease Drugs opportunities in our groundbreaking Parkinson's Disease Research and development projects @ Parkinson's Disease Unmet Needs [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Parkinson's Disease Companies and Drugs
* Cerevel Therapeutics: Tavapadon
* Pharma Two B Ltd: P2B001
* Hoffman-La Roche: Prasinezumab
* FAScinate Therapeutics: KM-819
* Peptron: PT320
* Vaxxinity Inc.: UB-312
Parkinson's Disease Market Drivers
* Increasing prevalence of Parkinson's Disease patients
* Robust clinical-stage pipeline
Parkinson's Disease Market Barriers
* Lack of awareness and delayed diagnosis
* Side effects associated with Parkinson's disease treatment drugs
Discover the latest advancements in Parkinson's Disease Treatment by visiting our website. Stay informed about how we're transforming the future of Neurology @ Parkinson's Disease Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Parkinson's Disease Pipeline Report
* Coverage- Global
* Parkinson's Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Prevail Therapeutics, Luye Pharma Group Ltd, FAScinate Therapeutics Inc., Neurocrine Biosciences, Sangamo Therapeutics, AstraZeneca, Hoffmann-La Roche, Brain Neurotherapy Bio, Inc, Annovis Bio Inc, Anavex Life Sciences Corp, Alexza Pharmaceuticals, Inc., Pharma Two B Ltd., MeiraGTx, LLC, BioVie Inc., Takeda Pharmaceuticals
* Parkinson's Disease Therapies- Apomorphine Infusion, CVN424 150 mg, MT101-5, BIA 28-6156 10 mg, RO7046015, ND0612, and others.
* Parkinson's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Parkinson's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Parkinson's Disease Pipeline on our website @ Parkinson's Disease Drugs and Companies [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Parkinson's disease : Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Tavapadon: Cerevel Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IkT-148009: Inhibikase Therapeutics
* Early Stage Products (Phase I )
* Product Name: Company Name
* Inactive Products
* Parkinson's disease Key Companies
* Parkinson's disease Key Products
* Parkinson's disease - Unmet Needs
* Parkinson's disease - Market Drivers and Barriers
* Parkinson's disease - Future Perspectives and Conclusion
* Parkinson's disease Analyst Views
* Parkinson's disease Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3557353 • Views: …
More Releases from ABNewswire
GetInsuredTexas.com Launches as the Essential Guide to Texas Insurance Policies, …
GetInsuredTexas.com, a new website from Baxter Insurance Agency, Inc., is now live, offering a one-stop shop for Texans to navigate the complexities of the state's insurance market, from understanding policies to comparing companies.
HOUSTON, TX - Jan 11, 2026 - Baxter Insurance Agency, Inc., a trusted name in the Texas insurance industry for over 40 years, is proud to announce the launch of GetInsuredTexas.com. This new platform is designed to be…
AI and the Future of the Translation Profession - Translation Conference to Deli …
Want to work smarter with AI - not just "go with the flow"? At the conference we'll share tools, methods, and practical workflows from the field - not just theory. Upgrade your professional toolkit.
The 2026 ITA hybrid translation conference will focus on one of the most urgent needs of today's language professionals: practical, applicable knowledge for working effectively - and responsibly - with artificial intelligence in real-world translation environments.
While public…
Caliente Brands Brings Bold Heat to Premium Beef Jerky Market with Authentic Spi …
Caliente Brands, LLC launches CalienteJerky.com, offering hickory-smoked beef jerky crafted exclusively from 100% USDA Approved Beef with uniquely spicy flavor profiles. The veteran-owned company targets consumers seeking bold, adventurous snack options with flavors ranging from Spicy Peppered to innovative Spicy Birria, delivering what the brand promises: where smoky and spicy meet delicious.
Caliente Brands, LLC has officially entered the premium beef jerky market with a clear mission: to deliver authentic spicy…
Patio Elegance Expands Luxury Collection to Create the Ultimate High-End Outdoor …
Patio Elegance announces an expanded portfolio of premium outdoor living solutions, ranging from professional-grade kitchen islands and grills to advanced wellness installations like cold plunges, jacuzzis, and handcrafted saunas. This comprehensive collection allows homeowners to design fully integrated, resort-style environments focused on culinary excellence, restorative wellness, and sophisticated comfort.
Patio Elegance is transforming how affluent homeowners approach outdoor living by offering a complete suite of luxury products that turn ordinary backyards…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
